Anthera Pharmaceuticals Inc ANTH Stock Analysis
- PINK
- Stock
- Market closed · opens Monday 9:30 AM ET
$0.00 unchanged at close Nov 6
Last close · Previous close $0.00
- 52-week change
- up $0.00, 9,900.00%Price only
- Distributions
- $0.00Per share, last 12 months
- Dividend yield
- NoneLast 12 months
Price chart
$0.00unchangedPast month
Use the left and right arrow keys to move along the chart.
Price data
Trading
- Previous close$0.00Nov 5
- Volume0.00Nov 6 session
Shares traded on all US exchanges in the last completed session. Live intraday volume covers IEX only, so it is left out.
- Avg. volume3.06KLast 21 sessions
The average daily shares traded over the last 21 trading sessions, about one calendar month.
- 52-week range: $0.00 to $0.00; now $0.00
The lowest and highest trades over the past 52 weeks, adjusted for splits. The marker shows the latest price.
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
Performance
Past performance, measured to the Nov 6 close. Total return includes reinvested dividends.Price change only, without dividends. Compared with the S&P 500, using SPY.
ANTH beat the S&P 500 in 4 of 7 periods.
| Period | ANTH and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | ANTH: unchanged S&P 500: down 5.6% | ANTH beat the S&P 500 by 5.6 percentage points Beat |
| 3M | ANTH: up 9,900.0% S&P 500: down 4.1% | ANTH beat the S&P 500 by 9,904.1 percentage points Beat |
| YTD | ANTH: unchanged S&P 500: up 8.7% | ANTH trailed the S&P 500 by 8.7 percentage points Trailed |
| 1Y | ANTH: up 9,900.0% S&P 500: up 10.9% | ANTH beat the S&P 500 by 9,889.1 percentage points Beat |
| Long term | ||
| 3Y | ANTH: unchanged S&P 500: up 75.0% 0.0% vs +20.5% a year | ANTH trailed the S&P 500 by 75.0 percentage points Trailed |
| 5Y | ANTH: up 9,900.0% S&P 500: up 67.8% +151.2% vs +10.9% a year | ANTH beat the S&P 500 by 9,832.2 percentage points Beat |
| 10Y | ANTH: down 100.0% S&P 500: up 313.1% −70.3% vs +15.2% a year | ANTH trailed the S&P 500 by 413.1 percentage points Trailed |
$10,000 invested in ANTH 10 years ago (Nov 4, 2016) would be worth about $0 at the close on , with dividends reinvested. The same amount in the S&P 500 would be worth about $41,313.
ANTH beat the S&P 500 in 4 of 7 periods.
| Period | ANTH and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | ANTH: unchanged S&P 500: down 5.6% | ANTH beat the S&P 500 by 5.6 percentage points Beat |
| 3M | ANTH: up 9,900.0% S&P 500: down 4.3% | ANTH beat the S&P 500 by 9,904.3 percentage points Beat |
| YTD | ANTH: unchanged S&P 500: up 7.8% | ANTH trailed the S&P 500 by 7.8 percentage points Trailed |
| 1Y | ANTH: up 9,900.0% S&P 500: up 9.7% | ANTH beat the S&P 500 by 9,890.3 percentage points Beat |
| Long term | ||
| 3Y | ANTH: unchanged S&P 500: up 68.8% 0.0% vs +19.1% a year | ANTH trailed the S&P 500 by 68.8 percentage points Trailed |
| 5Y | ANTH: up 9,900.0% S&P 500: up 56.9% +151.2% vs +9.4% a year | ANTH beat the S&P 500 by 9,843.1 percentage points Beat |
| 10Y | ANTH: down 100.0% S&P 500: up 252.6% −70.3% vs +13.4% a year | ANTH trailed the S&P 500 by 352.6 percentage points Trailed |
$10,000 invested in ANTH 10 years ago (Nov 4, 2016) would be worth about $0 at the close on , not counting dividends. The same amount in the S&P 500 would be worth about $35,257.
All-time high
$553.60
Closing high on . Now 100.0% below that record.
Split-adjusted daily closes since Mar 1, 2010.
Stock splits
2
Latest: 1-for-8 on . Share counts adjust after each split.
Both splits
- 1-for-8
- 1-for-8
About Anthera Pharmaceuticals Inc
Anthera Pharmaceuticals, Inc. (Anthera) is a development-stage, biopharmaceutical Company focused on developing and commercializing products to treat diseases associated with inflammation. As of December 31, 2011, the Company had one Phase-II clinical program, blisibimod. Two of its product candidates, varespladib and varespladib sodium, are designed to inhibit an enzyme target known as secretory phospholipase A2 (sPLA2). sPLA2 have been implicated in a range of acute inflammatory conditions, including acute coronary syndrome and acute chest syndrome associated with sickle cell disease, as well as in chronic diseases, including stable coronary artery disease (CAD). In addition, blisibimod targets B-lymphocyte stimulator (BLyS), also known as B-cell Activating Factor (BAFF), which has been associated with a range of B-cell mediated autoimmune diseases.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- California, USA
- SEC filings
- EDGAR (opens in a new tab)
- Exchange
- PINK
- Asset type
- Common stock
- Price history since
ANTH news
Explore more stocks
Prices are from the last refresh. Open any stock for its live dashboard.
Popular stocks
ANTH stock FAQ
What is ANTH stock’s price today?
Anthera Pharmaceuticals (ANTH) traded at $0.00 at the close on , unchanged from the previous close of $0.00. Over the past 52 weeks it has traded between $0.00 and $0.00.
If you invested $1,000 in ANTH 10 years ago, how much would you have now?
With dividends reinvested, $1,000 invested in ANTH on would be worth about $0 at the close on , a total return of −100.0%. The same $1,000 would be worth $100,000 if invested five years ago and $100,000 if invested one year ago. Past performance doesn’t predict future returns.
What is Anthera Pharmaceuticals’s market cap?
Anthera Pharmaceuticals’s market capitalization is about $2.3 thousand. That’s Tiingo’s daily market cap for , at that day’s closing price of $0.00 (how market cap works).
Does ANTH pay a dividend?
Anthera Pharmaceuticals hasn’t paid a dividend in the last twelve months.
What is ANTH’s 52-week high and low?
Over the past 52 weeks ANTH has traded as low as $0.00 and as high as $0.00. At $0.00 at the close on , it is 90.0% below that high and 9,900.0% above the low.
What is ANTH’s all-time high?
ANTH’s highest closing price was $553.60 on , adjusted for stock splits. At $0.00 at the close on , it is 100.0% below that record.
Has ANTH stock ever split?
Yes, twice: 1-for-8 on ; 1-for-8 on .
How has ANTH stock performed?
Including dividends and measured to the close on , ANTH has returned 0.0% so far this year and +9,900.0% over the past year, and +9,900.0% over five years (+151.2% a year). Over the same periods the S&P 500, measured by SPY, returned +8.7%, +10.9% and +67.8%. Past performance doesn’t predict future returns.
What sector and industry is Anthera Pharmaceuticals in?
Anthera Pharmaceuticals is in the Healthcare sector and the Biotechnology industry, and is headquartered in California, USA.
What exchange does ANTH trade on?
Anthera Pharmaceuticals trades on the PINK under the ticker symbol ANTH. Its price history on this dashboard begins on .
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
About this data. Data sourced by Tiingo (opens in a new tab). The live price is Tiingo’s real-time price, based on IEX trades and quotes; intraday charts show IEX trades, and volume figures are consolidated totals for completed sessions. Prices are split-adjusted, and total returns assume dividends are reinvested. Financials come from company filings and can lag new reports. Times are Eastern.
This page is for education, not investment advice. Past performance doesn't predict future returns. Logos provided by Logo.dev (opens in a new tab).
The Interactive Brokers word and logo are trademarks of Interactive Brokers LLC (or its subsidiaries) in the US and/or elsewhere. All rights reserved.